ATLASATLAS fair value
HK$39.10
Above fair value · 28% premium
Range: HK$30–HK$51Fair valuePrice
Shanghai Henlius Biotech (2696.HK)
Shanghai Henlius Biotech share price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Hong Kong Exchanges (HKEX) · Hong Kong SAR China
HK$49.86▼ -2.24%
Prices as of Oct 27, 2026 · HKD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Shanghai Henlius Biotech in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Shanghai Henlius Biotech
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Shanghai Henlius Biotech's fair value at about HK$39.10 per share (reasonable range: HK$29.89 to HK$51.15). At HK$49.86, the stock trades 28% above it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Shanghai Henlius Biotech a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between HK$44.26 and HK$54.98; in 9 out of 10, between HK$36.52 and HK$66.64. Estimated annual volatility is 65%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- HK$29.6B
- Market cap (USD)
- $3.8B
- P/E ratio
- 30.9
- 52-week high
- HK$87.10
- 52-week low
- HK$47.62
- Revenue (12 months)
- CN¥7.4B
- Gross margin
- 74.7%
- Operating margin
- 14.2%
- Net margin
- 11.7%
- Beta
- 0.52
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Shanghai Henlius Biotech sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks 2696.HK has traded between HK$47.62 and HK$87.10. Today it is 42.8% below that high and 5% above its low.
On the business: net margin is 11.7%; it trades at 30.9 times earnings.
Its beta is 0.52: it tends to move less than the market.
About the company
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.
Want to see everything about Shanghai Henlius Biotech?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Shanghai Henlius Biotech (2696.HK) fair value?
About HK$39.10 per share according to ATLAS (reasonable range: HK$29.89 to HK$51.15). With the stock at HK$49.86, it is 28% above it.
What is the chance 2696.HK goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, 2696.HK ends the month between HK$44.26 and HK$54.98.
How big is Shanghai Henlius Biotech and what is its P/E ratio?
Shanghai Henlius Biotech's market capitalization is HK$29.6B. Its price-to-earnings (P/E) ratio is 30.9: you pay HK$30.9 for each HK$1.00 of yearly earnings.
How volatile is 2696.HK?
ATLAS estimates annual volatility at 65%. In a typical month, half of the outcomes end between HK$44.26 and HK$54.98.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer